

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

PFIZER INC.,  
Petitioner,

v.

SANOFI-AVENTIS DEUTSCHLAND GMBH,  
Patent Owner.

---

Case IPR2019-00978  
Patent Number: 8,603,044

---

**PATENT OWNER'S MANDATORY NOTICES**  
**PURSUANT TO 37 C.F.R. § 42.8**

Patent Owner, Sanofi-Aventis Deutschland GmbH, hereby submits its mandatory notices pursuant to 37 C.F.R. § 42.8(a)(2).

**A. Real Party-In-Interest (37 C.F.R. § 42.8(b)(1))**

The real parties-in-interest are the following: Sanofi-Aventis Deutschland GmbH (patent owner of U.S. Patent No. 8,603,044 (“the ’044 Patent”)), Sanofi-Aventis U.S. LLC (exclusive licensee of the ’044 Patent), and Sanofi Winthrop Industrie (exclusive licensee of the ’044 Patent). Evidence supporting Sanofi-Aventis Deutschland GmbH’s status as the patent owner is found on the face of the ’044 Patent.

**B. Related Matters (37 C.F.R. § 42.8(b)(2))**

The following judicial and/or administrative proceedings could affect, or be affected by, a decision in this proceeding:

- *Sanofi-Aventis U.S. LLC, Sanofi-Aventis Deutschland GmbH, Sanofi Winthrop Industrie v. Mylan GmbH, Biocon Ltd., Biocon Research Ltd., Biocon Sdn. Bhd. and Biocon S.A.*, Case No. 2-17-cv-09105-SRC-CLW, U.S. District Court for New Jersey;
- *Sanofi-Aventis U.S. LLC, Sanofi-Aventis Deutschland GmbH, and Sanofi Winthrop Industrie v. Merck Sharp & Dohme Corp.*, Case No. 1-16-cv-00812-RGA-MPT, U.S. District Court for the District of Delaware;
- *Sanofi-Aventis U.S. LLC, Sanofi-Aventis Deutschland GmbH v. Eli Lilly and Company*, Case No. 1-14-cv-00113-RGA-MPT, U.S. District Court for the District of Delaware;
- *Mylan Pharmaceuticals Inc. v. Sanofi-Aventis Deutschland GmbH*, IPR2018-01670, Patent Trial and Appeal Board, U.S. Patent and Trademark Office, involving U.S. Patent No. 8,679,069;

- *Mylan Pharmaceuticals Inc. v. Sanofi-Aventis Deutschland GmbH*, IPR2018-01675, Patent Trial and Appeal Board, U.S. Patent and Trademark Office, involving U.S. Patent No. 8,603,044;
- *Mylan Pharmaceuticals Inc. v. Sanofi-Aventis Deutschland GmbH*, IPR2018-01676, Patent Trial and Appeal Board, U.S. Patent and Trademark Office, involving U.S. Patent No. 8,603,044;
- *Mylan Pharmaceuticals Inc. v. Sanofi-Aventis Deutschland GmbH*, IPR2018-01678, Patent Trial and Appeal Board, U.S. Patent and Trademark Office; involving U.S. Patent No.8,992,486;
- *Mylan Pharmaceuticals Inc. v. Sanofi-Aventis Deutschland GmbH*, IPR2018-01679, Patent Trial and Appeal Board, U.S. Patent and Trademark Office, involving U.S. Patent No.8,992,486;
- *Mylan Pharmaceuticals Inc. v. Sanofi-Aventis Deutschland GmbH*, IPR2018-01680, Patent Trial and Appeal Board, U.S. Patent and Trademark Office, involving U.S. Patent No. 9,526,844;
- *Mylan Pharmaceuticals Inc. v. Sanofi-Aventis Deutschland GmbH*, IPR2018-01682, Patent Trial and Appeal Board, U.S. Patent and Trademark Office, involving U.S. Patent No. 9,526,844;
- *Mylan Pharmaceuticals Inc. v. Sanofi-Aventis Deutschland GmbH*, IPR2018-01684, Patent Trial and Appeal Board, U.S. Patent and Trademark Office, involving U.S. Patent No. 9,604,008;
- *Mylan Pharmaceuticals Inc. v. Sanofi-Aventis Deutschland GmbH*, IPR2019-00122, Patent Trial and Appeal Board, U.S. Patent and Trademark Office, involving U.S. Patent No.8,992,486;
- *Pfizer Inc. v. Sanofi-Aventis Deutschland GmbH*, IPR2019-00977, Patent Trial and Appeal Board, U.S. Patent and Trademark Office, involving U.S. Patent No. 8,603,044;
- *Pfizer Inc. v. Sanofi-Aventis Deutschland GmbH*, IPR2019-00979, Patent Trial and Appeal Board, U.S. Patent and Trademark Office, involving U.S. Patent No. 8,679,069;

- *Pfizer Inc. v. Sanofi-Aventis Deutschland GmbH*, IPR2019-00980, Patent Trial and Appeal Board, U.S. Patent and Trademark Office; involving U.S. Patent No.8,992,486;
- *Pfizer Inc. v. Sanofi-Aventis Deutschland GmbH*, IPR2019-00981, Patent Trial and Appeal Board, U.S. Patent and Trademark Office; involving U.S. Patent No.8,992,486;
- *Pfizer Inc. v. Sanofi-Aventis Deutschland GmbH*, IPR2019-00982, Patent Trial and Appeal Board, U.S. Patent and Trademark Office, involving U.S. Patent No.8,992,486;
- *Pfizer Inc. v. Sanofi-Aventis Deutschland GmbH*, IPR2019-00987, Patent Trial and Appeal Board, U.S. Patent and Trademark Office, involving U.S. Patent No. 9,604,008;
- *Pfizer Inc. v. Sanofi-Aventis Deutschland GmbH*, IPR2019-01022, Patent Trial and Appeal Board, U.S. Patent and Trademark Office, involving U.S. Patent No. 9,526,844; and
- *Pfizer Inc. v. Sanofi-Aventis Deutschland GmbH*, IPR2019-01023, Patent Trial and Appeal Board, U.S. Patent and Trademark Office, involving U.S. Patent No. 9,526,844.

The '044 Patent, U.S. Application No. 13/909,649, is a continuation of U.S. Patent Application No. 12/944,544, now U.S. Patent No. 8,679,069, which is a continuation of U.S. Patent Application No. 11/483,546, now U.S. Patent No. 7,918,833, which is a continuation of U.S. Patent Application No. 10/790,225, now abandoned, and claims priority to GB Patent Application No. 0304822.

No U.S. patents or U.S. patent applications claim priority to the '044 Patent.

The following additional U.S. patents and U.S. patent applications claim priority to one or more of the same application(s) to which the '044 Patent claims

priority:

- U.S. Patent Application No. 10/790,866
- U.S. Patent Application No. 15/681,604
- U.S. Patent Application No. 15/787,737
- U.S. Patent Application No. 16/385,682
- U.S. Patent Application No. 12/320,189, now U.S. Pat. No. 7,850,662
- U.S. Patent Application No. 11/520,598, now U.S. Pat. No. 7,935,088
- U.S. Patent Application No. 13/040,198, now U.S. Pat. No. 8,512,297
- U.S. Patent Application No. 13/075,212, now U.S. Pat. No. 8,556,864
- U.S. Patent Application No. 13/909,681, now U.S. Pat. No. 8,992,486
- U.S. Patent Application No. 13/919,251, now U.S. Pat. No. 9,011,391
- U.S. Patent Application No. 12/941,702, now U.S. Pat. No. 9,028,454
- U.S. Patent Application No. 12/357,899, now U.S. Pat. No. 9,205,197
- U.S. Patent Application No. 14/635,573, now U.S. Pat. No. 9,233,211
- U.S. Patent Application No. 14/946,203, now U.S. Pat. No. 9,408,979
- U.S. Patent Application No. 15/156,616, now U.S. Pat. No. 9,526,844
- U.S. Patent Application No. 14/319,379, now U.S. Pat. No. 9,533,105
- U.S. Patent Application No. 14/319,384, now U.S. Pat. No. 9,561,331
- U.S. Patent Application No. 14/319,388, now U.S. Pat. No. 9,604,008
- U.S. Patent Application No. 14/319,394, now U.S. Pat. No. 9,604,009

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.